

# Predictors of diagnosis of non-affective acute remitting psychosis in patients with early-onset first psychotic episodes

**L. Pina-Camacho<sup>a</sup>, M. Parellada<sup>a</sup>, J. García-Prieto<sup>b</sup>, J. Castro-Fornieles<sup>c</sup>, A. Gonzalez-Pinto<sup>d</sup>, M. Graell<sup>e</sup>, S. Otero<sup>f</sup>, D. Moreno<sup>a</sup>, C. Arango<sup>a</sup>**

<sup>a</sup> Child and Adolescent Psychiatry Department, CIBERSAM, Instituto de Investigación Sanitaria Gregorio Marañón, IISGM, Hospital General Universitario Gregorio Marañón, Madrid, Spain


<sup>b</sup> Centre for Biomedical Technology (CTB) Universidad Politécnica de Madrid, Laboratory of Cognitive and Computational Neuroscience, Madrid, Spain

<sup>c</sup> Department of Child and Adolescent Psychiatry and Psychology, Institut Clinic de Neurociències, IDIBAPS, SGR-1119, Hospital Clinic of Barcelona, Department of Psychiatry and Psychobiology, University of Barcelona, CIBERSAM, Spain

<sup>d</sup> Stanley Institute International Mood Disorders Research Center, 03-RC-003, Hospital Santiago Apóstol, Vitoria, CIBERSAM, Spain

<sup>e</sup> Sección de Psiquiatría y Psicología, Hospital Infantil Universitario Niño Jesús, CIBERSAM, Madrid, Spain

<sup>f</sup> Unidad de Psiquiatría Infantil, Hospital Universitario Marqués de Valdecilla, CIBERSAM, Santander, Spain



## INTRODUCTION

• Most patients diagnosed with a non-affective acute remitting psychosis (NARP), such as schizophreniform disorder (SFD) or brief reactive psychosis (BRP), are later re-diagnosed with a chronic psychosis (CP), such as schizophrenia (SCZ) or affective psychoses (AP)<sup>1</sup>.

• However, in a small group of patients, the psychotic episode remits within six months and the diagnosis does not change<sup>1</sup>.

• Patients with NARP have a better long-term course and outcome, with a shorter disease duration, and little or no social and occupational impairment, compared with patients with CP<sup>2</sup>.

## HYPOTHESES

• Patients with first episodes of NARP have less disability, a better symptom profile, and functioning and insight during the first psychotic episode than those with CP.

• Better global functioning during the first psychotic episode and better premorbid adjustment predict a diagnosis of NARP at follow-up.

## METHODS

### The 'CAFEPS' study<sup>3</sup> (prospective longitudinal study)

110 patients  
98 healthy controls  
(9-17 years of age)



BASELINE	1 m	2 m	6 m	12 m	24 m
Sociodemographic and clinical data			Clinical data	Clinical data	Clinical data
Blood work (TAOS, genetics, immunology)	Blood work (TAOS, genetics, immunology)	Blood work (TAOS, genetics, immunology)	Blood work (TAOS, genetics, immunology)	Blood work (TAOS, genetics, immunology)	Blood work (TAOS, genetics, immunology)
Diagnosis K-SADS			Clinical diagnosis	Diagnosis K-SADS	Diagnosis K-SADS
	Cognitive assessment				Cognitive assessment

### 101 patients with STABLE DIAGNOSIS

at 6, 12, or 24 month follow-up

(15.5±1.8 years of age, 69.3% males)

PATIENTS with NARP (N=8)	PATIENTS with CP (N=93)
SFD (N=6) BRP (N=2)	SCZ (N=50) BD (N=25) SAD (N=7) PNOS (N=11)

\*Abbreviations: SFD=schizophreniform disorder, BRP=brief reactive psychosis, SCZ=schizophrenia, BD=bipolar disorder, SAD=schizoaffective disorder, PNOS=psychotic disorder not otherwise specified

### Analytic procedures

I) Differences between diagnostic groups in variables at baseline by means of a chi square test for categorical variables and paired t-test or Mann-Whitney test for continuous variables

II) Baseline factors predicting diagnosis of NARP at two-year follow-up → Forward-step logistic regression model

## RESULTS

### I) Differences between diagnostic groups at baseline

	NARP (N=8)	CP (N=93)	p-value
Age (y), mean (SD)	15.13	15.53	NS
Gender male/female (N)	6/2	64/29	NS
Ethnicity (Caucasian/Hispanic/Other), N	6/0/2	82/6/5	NS
Parental years of education, mean (SD)	12.63 (6.39)	10.51 (4.71)	NS
History of emergency C-section, N (%)	0 (0%)	12 (13.6%)	<b>0.04</b>
CGI-S, mean (SD)	3.75 (2.66)	5.67 (0.96)	<b>&lt;0.001</b>
c-GAF score, mean (SD)	45.00 (20.35)	31.97 (14.09)	<b>0.017</b>
DUP in days, mean (SD)	81.75 (64.07)	62.60 (49.97)	NS
PANSS positive score, mean (SD)	21.38 (6.44)	24.46 (6.44)	NS
PANSS negative score, mean (SD)	19.38 (6.26)	20.06 (9.26)	NS
PANSS general score, mean (SD)	40.88 (9.89)	45.00 (10.74)	NS
PANSS total score, mean (SD)	81.63 (18.06)	89.53 (20.38)	NS
PANSS item G12 (insight), mean (SD)	3.38 (1.85)	4.63 (1.67)	<b>0.045</b>
DAS score, mean (SD)	9.29 (5.76)	12.26 (3.25)	<b>0.049</b>
SCOS total score, mean (SD)	57.50 (5.86)	51.55 (7.66)	<b>0.035</b>

**No other differences (developmental or obstetric complication history, somatic disease history, family psychiatric history, symptom profile, substance abuse history, suicidal behaviour, premorbid adjustment or cognitive domains)**

### II) Baseline factors predicting diagnosis of NARP at two-year follow-up

Logistic Regression - Method Forward (conditional)								
	B	S.E.	Wald	df	Sig.	Exp(B)	Sig. Model	Nagelkerke R Square
c-GAF	-0.056	0.025	4.938	1	0.026	0.946	0.003	0.121
Constant	4.58	1.136	16.253	1	<0.001	97.504		

**Dependent variable:** NARP diagnosis

**Predictors:**

**Included:** c-GAF score

**Excluded:** gender, history of emergency C-section, CGI-S, PANSS negative score, PANSS item G12 (insight), SCOS total score, DAS total score

**c-GAF score at baseline predicts a diagnosis of NARP at follow-up**

## CONCLUSIONS

**1. During the first psychotic episode, children and adolescents with NARP have less disability and better functioning and insight than those with CP**

**2. Better functioning during the first psychotic episode predicts a diagnosis of NARP at follow-up**

## References

- Castro-Fornieles J., et al., Two-year diagnostic stability in early-onset first-episode psychosis. J Child Psychol Psychiatry, 2011. 52(10): p. 1089-98.
- Jablensky, A., Classification of nonschizophrenic psychotic disorders: a historical perspective. Curr Psychiatry Rep, 2001. 3(4): p. 326-31.
- Castro-Fornieles J, et al. (2007) The Child and Adolescent First-Episode Psychosis Study (Cafeps): Design and Baseline Results. Schizophr Res; 91(1-3):226-37.

**Funding Sources:** Supported by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, CIBERSAM, the Autonomous Community of Madrid, I+D Biomedicine, S2010/BMD-2422 AGES (Madrid, Spain), Fundación Mutua Madrileña, and "NARSAD 2005: Independent Investigator Award".

**Disclosures:** Dr. Pina-Camacho has received grants from Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, and Fundación Alicia Koplowitz. Dr. Parellada has no conflicts of interest for the past 5 years (previously, investigator in clinical trials funded by AstraZeneca, and travel assistance from Janssen and Lilly). Dr. Arango has served as a consultant for or has received honoraria or grant/research support from AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Pfizer, Roche, Servier, Schering-Plough, Stanley Foundation, Caja Navarra, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, Fundación Marcelino Botín, NARSAD, Autonomous Community of Madrid, Spanish Ministry of Education, Spanish Ministry of Health and Spanish Ministry of Economy and Competitiveness. The rest of authors have no conflicts to disclose.